Literature DB >> 16931212

Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease.

Daniel E Weiner1, Sayed Tabatabai, Hocine Tighiouart, Essam Elsayed, Nisha Bansal, John Griffith, Deeb N Salem, Andrew S Levey, Mark J Sarnak.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a risk factor for cardiovascular disease (CVD). Concurrently, CVD may promote CKD, resulting in a vicious cycle. We evaluated this hypothesis by exploring whether CKD and CVD have an additive or synergistic effect on future cardiovascular and mortality outcomes.
METHODS: Patients were pooled from 4 community-based studies: Atherosclerosis Risk in Communities, Framingham Heart, Framingham Offspring, and Cardiovascular Health Study. CKD is defined by an estimated glomerular filtration rate less than 60 mL/min/1.73 m(2) (<1 mL/s/1.73 m(2)). Baseline CVD included myocardial infarction, angina, stroke, transient ischemic attack, claudication, heart failure, and coronary revascularization. The primary outcome is a composite of cardiac events, stroke, and death. Secondary outcomes included individual components. Multivariable analyses using Cox regression examined differences in study outcomes. The interaction of CKD and CVD was tested.
RESULTS: The study population included 26,147 individuals. During 10 years, 4% (n = 2,927) of individuals with no CKD or CVD developed the primary outcome, 33% (n = 518) with only CKD, 37% (n = 1,260) with only CVD, and 66% (n = 459) with both. Both CKD (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.16 to 1.35; P < 0.0001) and CVD (HR, 1.83; 95% CI, 1.72 to 1.95; P < 0.0001) were independent risk factors for the primary outcome. The interaction term CKD x CVD was not statistically significant (HR, 0.98; 95% CI, 0.85 to 1.13; P = 0.74). Similar results were obtained for secondary outcomes.
CONCLUSION: CKD and CVD are both strong independent risk factors for adverse cardiovascular and mortality outcomes in the general population. Although individuals with both risk factors are at extremely high risk, there does not appear to be a synergistic effect of CKD and CVD on outcomes.

Entities:  

Mesh:

Year:  2006        PMID: 16931212     DOI: 10.1053/j.ajkd.2006.05.021

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  91 in total

Review 1.  Atherosclerosis in CKD: differences from the general population.

Authors:  Tilman B Drüeke; Ziad A Massy
Journal:  Nat Rev Nephrol       Date:  2010-10-26       Impact factor: 28.314

2.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

Review 3.  [Indications for parathyroidectomy in renal hyperparathyroidism: comments on the significance of new therapeutics].

Authors:  C Dotzenrath
Journal:  Chirurg       Date:  2010-10       Impact factor: 0.955

Review 4.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

5.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

6.  Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Usman Baber; Virginia J Howard; Jonathan L Halperin; Elsayed Z Soliman; Xiao Zhang; William McClellan; David G Warnock; Paul Muntner
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-11-13

7.  As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Authors:  A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich
Journal:  Rheumatol Int       Date:  2013-09-12       Impact factor: 2.631

8.  Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.

Authors:  D E Weiner; M A Carpenter; A S Levey; A Ivanova; E H Cole; L Hunsicker; B L Kasiske; S J Kim; J W Kusek; A G Bostom
Journal:  Am J Transplant       Date:  2012-05-17       Impact factor: 8.086

9.  Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders.

Authors:  Daniel E Weiner; Keith Bartolomei; Tammy Scott; Lori Lyn Price; John L Griffith; Irwin Rosenberg; Andrew S Levey; Marshal F Folstein; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2008-12-12       Impact factor: 8.860

10.  Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure.

Authors:  Iris J Lee; Brendan Hilliard; Abhishek Swami; John C Madara; Swati Rao; Tapan Patel; John P Gaughan; Jean Lee; Crystal A Gadegbeku; Eric T Choi; Philip L Cohen
Journal:  Nephrol Dial Transplant       Date:  2012-08-20       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.